NeoFipronis (Pronidesivir) Full Prescribing Information
NeoFipronis (Pronidesivir) is an oral FIP treatment for cats formulated with GS-441524, a nucleoside analog studied extensively for its antiviral activity against feline coronavirus. According to manufacturer information, NeoFipronis is the first globally approved oral FIP medication officially registered by the Lao Ministry of Agriculture and Forestry (MAF) in March 2026, making it a notable option for cats affected by feline infectious peritonitis. It is designed for fast absorption, convenient daily administration, and generally good tolerance, with a low incidence of side effects when used appropriately.
Feline infectious peritonitis, or FIP, is a serious and often life-threatening disease caused by a mutation of feline coronavirus. Common FIP symptoms include poor appetite, lethargy, fever, abdominal fluid buildup, pleural effusion, enlarged lymph nodes, inflammatory granulomas, neurological signs, and eye problems such as uveitis. NeoFipronis (Pronidesivir) is intended to help manage these FIP-related manifestations by targeting viral replication, which may support clinical improvement in both wet FIP and dry FIP, including neurological and ocular forms.
Active Ingredient and Mechanism
The active ingredient in NeoFipronis is GS-441524, which has been widely researched and used in veterinary practice for FIP management. By interfering with viral RNA replication, GS-441524 helps reduce the viral burden in infected cats. This antiviral mechanism is the reason NeoFipronis is often considered a practical oral choice for cat owners seeking effective, non-invasive support for FIP treatment.
Dosage and Administration
NeoFipronis should be dosed according to body weight. The standard recommended dose is 15 mg per kilogram of body weight once daily, which is approximately half a tablet per kilogram, depending on the tablet strength. For neurological FIP or ocular FIP, veterinarians may advise increasing the dose to 30 mg per kilogram once daily based on the cat’s condition and response to treatment.
For best absorption, it is generally recommended to give NeoFipronis on an empty stomach, either one hour before feeding or two hours after a meal. Daily consistency matters, and treatment should be given at the same time each day whenever possible.
Treatment Duration and Monitoring
Cats with FIP typically require continuous treatment for at least 12 weeks, and doses should not be skipped. Missing doses may reduce treatment effectiveness and delay recovery. During therapy, caregivers should monitor appetite, body temperature, energy level, hydration, and overall behavior. Regular veterinary follow-up is also important, including blood tests and liver and kidney function checks, to ensure the cat is responding well and tolerating treatment.
Precautions and Warnings
Although NeoFipronis is described as an over-the-counter veterinary product, use under a veterinarian’s guidance is strongly recommended. This is especially important for kittens, older cats, cats with advanced disease, or cats with neurological and ocular involvement. NeoFipronis is for cats only and must not be used in humans. Keep the product out of reach of children and store it according to the manufacturer’s instructions.
Why NeoFipronis for FIP Treatment
NeoFipronis (Pronidesivir) is valued for its oral convenience, rapid absorption, and generally favorable tolerance profile. For cat owners dealing with the stress of FIP, it offers a practical treatment pathway that may help cats regain appetite, reduce fever, improve activity, and support recovery from fluid accumulation and inflammatory symptoms. For product authenticity and quality assurance, purchase only through the official NeoFipronis website or authorized channels.
